| SYS | | 0059980 |
|---|
| LBL | | 00000naa^^22^^^^^^^^450 |
|---|
| 005 | | 20110518155635.0 |
|---|
| 100 | | $a 20110315a2011 m y0sloy0103 ba |
|---|
| 101 | 0- | $a eng |
|---|
| 102 | | $a SK |
|---|
| 200 | 1- | $a Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial $f J. Ocvirk ... [et al.] |
|---|
| 305 | | $a World J Gastroenterol. 2010 Jul 7, 16(25): 3133-43 |
|---|
| 463 | -1 | $1 001 sllk_un_cat*0059831 $1 011 $a 1336-8176 $1 200 1 $a Onkológia $v Roč. 6, č. 1 (2011), s. 56 $1 210 $a Bratislava $c SOLEN $d 2011 $1 215 $a s. 4-62 |
|---|
| 541 | 1- | $a Cetuximab plus FOLFOX6 alebo FOLFIRI pri metastatickom karcinóme kolorekta: štúdia CECOG $z slo |
|---|
| 606 | 1- | $3 sllk_un_auth*d015179 $a nádory kolorektálne $x farmakoterapia $2 mesh |
|---|
| 606 | 1- | $3 sllk_un_auth*d004359 $a farmakoterapia kombinovaná $2 mesh |
|---|
| 606 | 1- | $3 sllk_un_auth*d054697 $a cytostatiká $x použitie terapeutické $2 mesh |
|---|
| 606 | 2- | $3 sllk_un_auth*d005472 $a fluorouracil $2 mesh |
|---|
| 606 | 2- | $3 sllk_un_auth*d005492 $a kyselina listová $2 mesh |
|---|
| 606 | 2- | $3 sllk_un_auth*d018572 $a prežívanie bez choroby $2 mesh |
|---|
| 606 | 2- | $3 sllk_un_auth*d016032 $a skúšanie randomizované kontrolované ako téma $2 mesh |
|---|
| 608 | | $3 sllk_un_auth*d004740 $a abstrakt v angličtine $2 mesh |
|---|
| 610 | 2- | $a cetuximab |
|---|
| 610 | 2- | $a oxaliplatina |
|---|
| 701 | -1 | $3 sllk_un_auth*0019757 $a Ocvirk $b J. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019732 $a Brodowicz $b T. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019758 $a Wrba $b F. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019759 $a Ciuleanu $b T. E. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019760 $a Kurteva $b G. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0010376 $a Beslija $b S. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*p0008801 $a Koza $b Ivan $f 1940-2021 $p Národný onkologický ústav, Bratislava $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019761 $a Pápai $b Z. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019762 $a Messinger $b D. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019764 $a Yilmaz $b U. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019765 $a Faluhelyi $b Z. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019766 $a Yalcin $b Suayib $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019767 $a Papamichael $b D. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019768 $a Wenczl $b M. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019769 $a Mrsic-Krmpotic $b Z. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019770 $a Shacham-Shmueli $b E. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019771 $a Vrbanec $b D. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019772 $a Esser $b R. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019773 $a Scheithauer $b W. $4 070 |
|---|
| 701 | -1 | $3 sllk_un_auth*0019742 $a Zielinski $b C. C. $4 070 |
|---|
| 801 | -0 | $a SK $b BA006 $c 20110315 $g AACR2 |
|---|
